Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speedApplication ...
Silexion Therapeutics (SLXN) announced the initiation of its regulatory application in Israel for its planned Phase 2/3 clinical trial of SIL204 ...
As India prepares for the upcoming union Budget, the PHD Chamber of Commerce and Industry (PHDCCI) has pitched for a decisive policy and investment push to strengthen agriculture, farmers'' welfare, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback